

Dr. Woltering's Research Lab For NET cancer needs support from the LSU Community for 2015.

Dr. Eugene Woltering is The James D. Rives Professor of Surgery and Neuroscience at LSU's School of Medicine. The LSUHSC Foundation is proud of the achievements of Dr. Woltering and his talented staff, both the research lab technicians and his surgical team which is internationally known and recognized as one of the top surgical teams and pioneers for NET (neuroendocrine) cancer. Both the team and Dr. Woltering speak at many conferences

sharing these techniques with their peer community. A visionary, Dr. Woltering has led the way to the acceptance of surgery as the first intervention to consider to treating NET cancer.

Funding for research in neuroendocrine tumors is extremely difficult to obtain from traditional sources like the National Cancer Institute and the American Cancer Society since funding research for more common disease populations will help many more patients. The NET Research Fund will be unable to continue its activities without a major financial boost in the next six months. Not only has the Kenner LA Neuroendocrine Tumor Program prolonged more than 3,000 lives, but Woltering's team has led groundbreaking research resulting in numerous medical advances that benefit NET patients. The Neuroendocrine Tumor Program at the Ochsner Medical Center in Kenner, Louisiana which Dr. Woltering founded, is one of the largest clinics in the United States specializing in diagnosing and treating NET patients.

Led by Dr. Woltering, whose long service to this community is legendary (thirty years), it serves patients from all but one state (Hawaii) and a number of foreign countries. The purpose of its related NET Research Fund is to help further the research and care of patients with these rare neuroendocrine tumors. The projects include:

- The maintenance of a tissue bank, containing more than 740 cryogenically frozen tumor tissue samples for research on the efficacy of treatments for NET cancer. Dr. Woltering uses the tissue samples obtained from life-saving surgeries performed by his surgical team which operates on many referrals from other surgeons.
- On-going research on the efficacy of black raspberry powder (BRP) as an anti-angiogenic. Dr. Woltering and LSUHSC mutually hold the patent on the use of black raspberry powder (BRP) as an anti-angiogenic agent for NETs. Dr. Woltering is the pioneer in this field for NET cancer. NETs and black raspberry powder could possibly be the alchemy to a cure for cancer. Who wouldn't want to support this cause? BRP is an anti-cancer strategy that prevents new blood vessels from growing and providing nutrients to tumors. Most of today's newest cancer drugs target rapidly dividing cells (which is why you lose your hair during chemotherapy); agents like BRP target only the cancer cells. Dr. Woltering's original research paper on BRP was one of the first published. The results are very, very promising but we need to keep up the momentum! Other researchers are now examining BRP as a possible anti-angiogenic agent for oral cancer, prostate and colon cancer. Dr. Woltering is on to something big!
- An elite researcher who holds 15 patents, Dr. Woltering has published 150 clinical papers as a direct result of his research; a number of the papers are considered to be seminal works in the field.

All proceeds will be used directly for the research and care of patients with neuroendocrine tumors. For more information, please email foundation@lsuhsc.edu or call: **504.568.3712**.

[CLICK HERE](#) to make a donation.

Select **"NET Carcinoid Cancer Fund"** in the Designation menu.